Literature DB >> 15678270

Approach to the assessment of platelet function: comparison between optical-based platelet-rich plasma and impedance-based whole blood platelet aggregation methods.

Anna M Dyszkiewicz-Korpanty1, Eugene P Frenkel, Ravindra Sarode.   

Abstract

Platelet aggregation studies play an important role in the assessment of hereditary and acquired platelet function defects. The first aggregation test introduced into laboratory practice used platelet-rich plasma (PRP) where aggregation was detected by an optical method. The assessment of platelet function using whole blood (WB) aggregation by an impedance method followed up nearly 20 years later. The WB impedance aggregation assay appears to be superior to the optical method because it 1) evaluates platelets in a physiologic milieu in the presence of red and white blood cells, which are known to modulate platelet function; 2) is faster; 3) has higher sensitivity; and 4) does not require centrifugation, thus avoiding injury to platelets and loss of giant thrombocytes. These two assays were compared. Clearly, the WB impedance aggregation methodology has many advantages over the optical PRP assay for the assessment of the hyperactive platelet syndrome and the effects of anti-platelet drugs.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15678270     DOI: 10.1177/107602960501100103

Source DB:  PubMed          Journal:  Clin Appl Thromb Hemost        ISSN: 1076-0296            Impact factor:   2.389


  18 in total

Review 1.  [Coronary stents, dual antiplatelet therapy and peri-operative problems].

Authors:  H Metzler; K Huber; S Kozek-Langenecker; M N Vicenzi; A Münch
Journal:  Anaesthesist       Date:  2007-04       Impact factor: 1.041

Review 2.  Introduction to haemostasis from a pharmacodynamic perspective.

Authors:  Cornelis Kluft; Jacobus Burggraaf
Journal:  Br J Clin Pharmacol       Date:  2011-10       Impact factor: 4.335

3.  Differences in Whole Blood Platelet Aggregation at Baseline and in Response to Aspirin and Aspirin Plus Clopidogrel in Patients With Versus Without Chronic Kidney Disease.

Authors:  Nishank Jain; Xilong Li; Beverley Adams-Huet; Ravi Sarode; Robert D Toto; Subhash Banerjee; S Susan Hedayati
Journal:  Am J Cardiol       Date:  2015-12-07       Impact factor: 2.778

4.  Flow diverter treatment of cerebral blister aneurysms.

Authors:  Russell Cerejo; Mark Bain; Seby John; Julian Hardman; Nina Moore; M Shazam Hussain; Gabor Toth
Journal:  Neuroradiology       Date:  2017-10-18       Impact factor: 2.804

5.  Prospective, observational study of antiplatelet and coagulation biomarkers as predictors of thromboembolic events after implantation of ventricular assist devices.

Authors:  Farhan Majeed; Willem J Kop; Robert S Poston; Seeta Kallam; Mandeep R Mehra
Journal:  Nat Clin Pract Cardiovasc Med       Date:  2009-02

6.  Platelet aggregation in rhesus macaques (Macaca mulatta) in response to short-term meloxicam administration.

Authors:  Keith E Anderson; Jamie Austin; Evelyn P Escobar; Larry Carbone
Journal:  J Am Assoc Lab Anim Sci       Date:  2013-09       Impact factor: 1.232

7.  Platelet aggregation in humans and nonhuman primates: relevance to xenotransplantation.

Authors:  Hayato Iwase; Burcin Ekser; Hao Zhou; Eefje M Dons; David K C Cooper; Mohamed B Ezzelarab
Journal:  Xenotransplantation       Date:  2012 Jul-Aug       Impact factor: 3.907

8.  The mouse mutation "thrombocytopenia and cardiomyopathy" (trac) disrupts Abcg5: a spontaneous single gene model for human hereditary phytosterolemia/sitosterolemia.

Authors:  Thomas H Chase; Bonnie L Lyons; Roderick T Bronson; Oded Foreman; Leah Rae Donahue; Lisa M Burzenski; Bruce Gott; Priscilla Lane; Belinda Harris; Uta Ceglarek; Joachim Thiery; Henning Wittenburg; Jonathan N Thon; Joseph E Italiano; Kenneth R Johnson; Leonard D Shultz
Journal:  Blood       Date:  2009-10-21       Impact factor: 22.113

9.  Increases in ambient particulate matter air pollution, acute changes in platelet function, and effect modification by aspirin and omega-3 fatty acids: A panel study.

Authors:  Adan Z Becerra; Steve Georas; J Thomas Brenna; Philip K Hopke; Cathleen Kane; David Chalupa; Mark W Frampton; Robert Block; David Q Rich
Journal:  J Toxicol Environ Health A       Date:  2016-03-30

10.  Rationale and design of the Chronic Kidney Disease Antidepressant Sertraline Trial (CAST).

Authors:  Nishank Jain; Madhukar H Trivedi; A John Rush; Thomas Carmody; Benji Kurian; Robert D Toto; Ravindra Sarode; S Susan Hedayati
Journal:  Contemp Clin Trials       Date:  2012-10-22       Impact factor: 2.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.